Fujifilm Biosciences launches first commercial HEK293 perfusion medium for gene therapy production
FUJIFILM Biosciences has introduced BalanCD HEK293 Perfusion A Medium, the first commercially available cell culture solution specifically optimised for HEK293 cells in perfusion processes. The medium targets gene therapy applications, enabling continuous production of adeno-associated virus (AAV) and lentivirus (LV) vectors with enhanced consistency and scalability.
Addressing critical manufacturing challenges
The new medium addresses key limitations in gene therapy production by supporting high cell density perfusion cultures. HEK293 cells are established workhorses in gene therapy upstream bioprocessing, offering reliable growth characteristics and high transfection efficiency essential for viral vector production.
BalanCD HEK293 Perfusion A demonstrates compatibility across multiple cell retention devices, providing operational flexibility for different manufacturing workflows. The medium supports both steady-state and intensified perfusion processes, accommodating various production strategies whilst maintaining cell viability and productivity.
“FUJIFILM Biosciences is committed to helping our partners bring innovative new treatments and therapies to more patients than ever before. With BalanCD HEK293 Perfusion A medium, we have introduced a new way to advance gene therapies, building on a family of purposely-designed, high performing HEK293 products to provide more consistent, high-quality resources across the treatment spectrum,” said Erik Vaessen, chief business officer, FUJIFILM Biosciences.
FUJIFILM Biosciences’
BalanCD HEK293,
Perfusion, A Medium
Technical specifications and applications
The medium enables process optimisation through maximised cell growth and productivity whilst supporting diverse applications including viral vector production, transient protein expression, and recombinant protein manufacturing. Its design accommodates different transfection methods, providing technical versatility for various experimental approaches.
Economic and operational benefits
By harnessing perfusion technology benefits, the medium enables reduction in capital expenditures associated with AAV and LV production. This economic advantage supports resource maximisation for consistency and scalability whilst providing clinical-quality media capable of supporting large-scale commercial batch production for advanced therapy development.
The launch expands FUJIFILM Biosciences’ gene therapy portfolio, offering continuous processing capabilities with optimal performance characteristics. Available in multiple media package configurations, the product addresses growing demand for reliable, efficient viral vector production platforms.
“This innovative approach is another example on how we are customising services, products, and systems to help all who bring therapeutics to more patients, as we continue to work on this mission together,” Vaessen added.
For more information, visit: https://fujifilmbiosciences.fujifilm.com
Digital issue: Please click here for more information
Erik Vaessen, Chief Business Officer, FUJIFILM Biosciences
